{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T05:43:48Z","timestamp":1789969428256,"version":"4.0.1"},"reference-count":146,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2004,6,1]],"date-time":"2004-06-01T00:00:00Z","timestamp":1086048000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2004,6,1]],"date-time":"2004-06-01T00:00:00Z","timestamp":1086048000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2004,6]]},"DOI":"10.1016\/j.biopha.2004.04.006","type":"journal-article","created":{"date-parts":[[2004,5,11]],"date-time":"2004-05-11T06:35:09Z","timestamp":1084257309000},"page":"299-309","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":37,"title":["Rituximab in autoimmune diseases"],"prefix":"10.1016","volume":"58","author":[{"given":"Luigi","family":"Virgolini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanda","family":"Marzocchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2004.04.006_BIB1","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1007\/s002770100340","article-title":"Severe Evans\u2019s syndrome secondary to interleukin-2 therapy: treatment with chimeric monoclonal anti-CD20 antibody","volume":"80","author":"Abdel-Raheem","year":"2001","journal-title":"Ann Hematol"},{"key":"10.1016\/j.biopha.2004.04.006_BIB2","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1002\/1529-0131(200003)43:3<608::AID-ANR18>3.0.CO;2-G","article-title":"Induction of tumor necrosis factor alpha production by adhered human monocytes: a key role for Fcgamma receptor type IIIa in rheumatoid arthritis","volume":"43","author":"Abrahams","year":"2000","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.biopha.2004.04.006_BIB3","first-page":"1209","article-title":"Rituximab: an anti-CD20 antibody for the treatment of chronic refractory immune thrombocytopenic purpura","volume":"95","author":"Aggarwal","year":"2002","journal-title":"South Med J"},{"key":"10.1016\/j.biopha.2004.04.006_BIB4","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1042\/bst0250705","article-title":"Targeted anti-cancer therapy using rituximab, a chimaeric anti-CD20 antibody (IDEC-C2B8) in the treatment of non-Hodgkin\u2019s B-cell lymphoma","volume":"25","author":"Anderson","year":"1997","journal-title":"Biochem Soc Trans"},{"key":"10.1016\/j.biopha.2004.04.006_BIB5","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1007\/s11926-003-0020-x","article-title":"B cell depletion therapy in systemic lupus erythematosus","volume":"5","author":"Anolik","year":"2003","journal-title":"Curr Rheumatol Rep"},{"issue":"2","key":"10.1016\/j.biopha.2004.04.006_BIB6","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/art.10764","article-title":"The relationship of FcgammaRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus","volume":"48","author":"Anolik","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.biopha.2004.04.006_BIB7","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1046\/j.1365-2141.2002.3317_3.x","article-title":"Restoration of erythropoiesis by rituximab in an adult patient with primary acquired pure red cell aplasia refractory to conventional treatment","volume":"116","author":"Auner","year":"2002","journal-title":"Br J Haematol"},{"key":"10.1016\/j.biopha.2004.04.006_BIB8","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1046\/j.1365-2141.2002.36892.x","article-title":"Successful response to rituximab in a patient with pure red cell aplasia complicating chronic lymphocytic leukaemia","volume":"118","author":"Batlle","year":"2002","journal-title":"Br J Haematol"},{"key":"10.1016\/j.biopha.2004.04.006_BIB9","doi-asserted-by":"crossref","first-page":"2771","DOI":"10.1182\/blood.V98.9.2771","article-title":"Complement-mediated cell death induced by rituximab in B-cell lymphoproliferative disorders is mediated in vitro by a caspase-independent mechanism involving the generation of reactive oxygen species","volume":"98","author":"Bellosillo","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.biopha.2004.04.006_BIB10","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1046\/j.1365-2141.2001.03078.x","article-title":"Favourable response to therapy with the anti-CD20 monoclonal antibody rituximab in primary chronic cold agglutinin disease","volume":"115","author":"Berentsen","year":"2001","journal-title":"Br J Haematol"},{"key":"10.1016\/j.biopha.2004.04.006_BIB11","first-page":"ECR01","article-title":"Autoimmune hemolytic anemia after treatment of severe systemic lupus erythematosus with high-dose chemotherapy and autotransplantation of selected peripheral hematopoietic progenitors","volume":"88","author":"Besalduch","year":"2003","journal-title":"Haematologica"},{"issue":"Suppl 8","key":"10.1016\/j.biopha.2004.04.006_BIB12","first-page":"S139","article-title":"Anti-CD4 therapy in rheumatoid arthritis","volume":"11","author":"Burmester","year":"1993","journal-title":"Clin Exp Rheumatol"},{"issue":"Suppl 1","key":"10.1016\/j.biopha.2004.04.006_BIB13","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1038\/sj.bmt.1703935","article-title":"Stem cell therapy for autoimmune disease: overview of concepts from the Snowbird 2002 tolerance and tissue regeneration meeting","volume":"32","author":"Burt","year":"2003","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.biopha.2004.04.006_BIB14","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1023\/A:1006638510160","article-title":"Intense immune suppression for systemic lupus\u2014the role of hematopoietic stem cells","volume":"20","author":"Burt","year":"2000","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.biopha.2004.04.006_BIB15","doi-asserted-by":"crossref","first-page":"3505","DOI":"10.1182\/blood.V92.10.3505","article-title":"Treatment of autoimmune disease by intense immunosuppressive conditioning and autologous hematopoietic stem cell transplantation","volume":"92","author":"Burt","year":"1998","journal-title":"Blood"},{"issue":"6\u00a0Suppl 12","key":"10.1016\/j.biopha.2004.04.006_BIB16","first-page":"91","article-title":"Overview of idiopathic thrombocytopenic purpura: new approach to refractory patients","volume":"27","author":"Bussel","year":"2000","journal-title":"Semin Oncol"},{"issue":"3","key":"10.1016\/j.biopha.2004.04.006_BIB17","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1182\/blood.V99.3.1038","article-title":"The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: evidence of caspase activation and apoptosis induction","volume":"99","author":"Byrd","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.biopha.2004.04.006_BIB18","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.1002\/art.11181","article-title":"Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritis","volume":"48","author":"Cambridge","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.biopha.2004.04.006_BIB19","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1182\/blood.V99.3.754","article-title":"Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene","volume":"99","author":"Cartron","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.biopha.2004.04.006_BIB20","first-page":"ELT23","article-title":"The place of rituximab in the treatment algorithm for post-stem cell transplant autoimmune hemolytic anemia","volume":"87","author":"Chakrabarti","year":"2002","journal-title":"Haematologica"},{"key":"10.1016\/j.biopha.2004.04.006_BIB21","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1002\/ajh.10204","article-title":"Successful treatment of severe thrombotic thrombocytopenic purpura with the monoclonal antibody rituximab","volume":"71","author":"Chemnitz","year":"2002","journal-title":"Am J Hematol"},{"key":"10.1016\/j.biopha.2004.04.006_BIB22","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/S0002-9343(02)01273-1","article-title":"Hereditary hemorrhagic telangiectasia, idiopathic thrombocytopenic purpura, and chronic lymphocytic leukemia treated with rituximab","volume":"113","author":"Choueiri","year":"2002","journal-title":"Am J Med"},{"key":"10.1016\/j.biopha.2004.04.006_BIB23","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1046\/j.1365-4362.2002.01407.x","article-title":"Immunoablative high-dose cyclophosphamide without stem cell rescue in pemphigus foliaceus","volume":"41","author":"Cohen","year":"2002","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.biopha.2004.04.006_BIB24","doi-asserted-by":"crossref","first-page":"279","DOI":"10.2174\/1381612033392134","article-title":"Treatment of refractory autoimmune diseases with ablative immunotherapy using monoclonal antibodies and\/or high dose chemotherapy with hematopoietic stem cell support","volume":"9","author":"Cohen","year":"2003","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.biopha.2004.04.006_BIB25","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.3109\/10428190109097770","article-title":"Monotherapy with rituximab induces rapid remission of recurrent cold agglutinin-mediated hemolytic anemia in a patient with indolent lympho-plasmacytic lymphoma","volume":"42","author":"Cohen","year":"2001","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.biopha.2004.04.006_BIB26","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/sj.thj.6200148","article-title":"Sustained complete remission of chronic refractory immune thrombocytopenic purpura (ITP) of 10\u00a0years duration after only two infusions of rituximab","volume":"3","author":"Cohen","year":"2002","journal-title":"Hematol J"},{"key":"10.1016\/j.biopha.2004.04.006_BIB27","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1046\/j.1365-2230.2003.01283.x","article-title":"Treatment of resistant pemphigus vulgaris with an anti-CD20 monoclonal antibody (rituximab)","volume":"28","author":"Cooper","year":"2003","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.biopha.2004.04.006_BIB28","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1159\/000067271","article-title":"Rituximab for immune hemolytic anemia following T- and B-cell-depleted hematopoietic stem cell transplantation","volume":"109","author":"Corti","year":"2003","journal-title":"Acta Haematol"},{"key":"10.1016\/j.biopha.2004.04.006_BIB29","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/S0248-8663(02)00700-2","article-title":"Safety of monoclonal antibody anti-CD 20\u00a0in refractory thrombocytopenic idiopathic purpura","volume":"23","author":"de Roux Serratrice","year":"2002","journal-title":"Rev Med Interne"},{"key":"10.1016\/j.biopha.2004.04.006_BIB30","first-page":"179","article-title":"Cyclophosphamide pulses in the treatment of rheumatic diseases: an update","volume":"9","author":"De Vita","year":"1991","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.biopha.2004.04.006_BIB31","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1002\/art.10467","article-title":"Efficacy of selective B cell blockade in the treatment of rheumatoid arthritis: evidence for a pathogenetic role of B cells","volume":"46","author":"De Vita","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.biopha.2004.04.006_BIB32","first-page":"215","article-title":"Anti-CD20 monoclonal antibody therapy in refractory immune thrombocytopenic purpura","volume":"87","author":"Delgado","year":"2002","journal-title":"Haematologica"},{"key":"10.1016\/j.biopha.2004.04.006_BIB33","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.4049\/jimmunol.171.3.1581","article-title":"Complement activation determines the therapeutic activity of rituximab in vivo","volume":"171","author":"Di Gaetano","year":"2003","journal-title":"J Immunol"},{"key":"10.1016\/j.biopha.2004.04.006_BIB34","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1002\/1529-0131(199909)42:9<1823::AID-ANR5>3.0.CO;2-X","article-title":"Fcgamma receptor polymorphisms in Wegener\u2019s granulomatosis: risk factors for disease relapse","volume":"42","author":"Dijstelbloem","year":"1999","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.biopha.2004.04.006_BIB35","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/S1471-4906(01)02014-2","article-title":"Inflammation in autoimmunity: receptors for IgG revisited","volume":"22","author":"Dijstelbloem","year":"2001","journal-title":"Trends Immunol"},{"key":"10.1016\/j.biopha.2004.04.006_BIB36","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1046\/j.1523-5394.2001.009002071.x","article-title":"Monoclonal antibody therapy for lymphoma: an update","volume":"9","author":"Dillman","year":"2001","journal-title":"Cancer Pract"},{"key":"10.1016\/j.biopha.2004.04.006_BIB37","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1016\/S0889-8588(05)70129-5","article-title":"Cryoglobulinemia","volume":"13","author":"Dispenzieri","year":"1999","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1016\/j.biopha.2004.04.006_BIB38","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1046\/j.1365-2567.1999.00772.x","article-title":"Do self-perpetuating B lymphocytes drive human autoimmune disease?","volume":"97","author":"Edwards","year":"1999","journal-title":"Immunology"},{"key":"10.1016\/j.biopha.2004.04.006_BIB39","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1042\/bst0300824","article-title":"B-lymphocyte depletion therapy in rheumatoid arthritis and other autoimmune disorders","volume":"30","author":"Edwards","year":"2002","journal-title":"Biochem Soc Trans"},{"key":"10.1016\/j.biopha.2004.04.006_BIB40","doi-asserted-by":"crossref","first-page":"551","DOI":"10.3109\/10428190109064616","article-title":"Remarkable response to rituximab in a 72-year-old patient with refractory non-Hodgkin\u2019s lymphoma and marrow aplasia","volume":"42","author":"Egerer","year":"2001","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.biopha.2004.04.006_BIB41","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1002\/j.1460-2075.1988.tb02867.x","article-title":"Molecular cloning of the human B cell CD20 receptor predicts a hydrophobic protein with multiple transmembrane domains","volume":"7","author":"Einfeld","year":"1988","journal-title":"EMBO J"},{"key":"10.1016\/j.biopha.2004.04.006_BIB42","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1007\/s00277-003-0740-z","article-title":"Successful treatment with rituximab for autoimmune hemolytic anemia concomitant with proliferation of Epstein\u2013Barr virus and monoclonal gammopathy in a post-nonmyeloablative stem cell transplant patient","volume":"83","author":"Endo","year":"2004","journal-title":"Ann Hematol"},{"key":"10.1016\/j.biopha.2004.04.006_BIB43","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1182\/blood-2002-04-1213","article-title":"Severe cold hemagglutinin disease (CHD) successfully treated with rituximab","volume":"100","author":"Engelhardt","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.biopha.2004.04.006_BIB44","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1007\/s00415-002-0800-7","article-title":"Hematopoietic stem cell transplantation for multiple sclerosis","volume":"249","author":"Fassas","year":"2002","journal-title":"J Neurol"},{"key":"10.1016\/j.biopha.2004.04.006_BIB45","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1034\/j.1600-0609.2001.066006408.x","article-title":"Sustained remission of platelet counts following monoclonal anti-CD20 antibody therapy in two cases of idiopathic autoimmune thrombocytopenia and neutropenia","volume":"66","author":"Faurschou","year":"2001","journal-title":"Eur J Haematol"},{"issue":"2","key":"10.1016\/j.biopha.2004.04.006_BIB46","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1046\/j.1365-2249.2000.01208.x","article-title":"The role of Fcgamma receptor polymorphisms and C3 in the immune defence against Neisseria meningitidis in complement-deficient individuals","volume":"120","author":"Fijen","year":"2000","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.biopha.2004.04.006_BIB47","doi-asserted-by":"crossref","first-page":"3753","DOI":"10.1182\/blood-2002-12-3920","article-title":"Acquired high-titer factor VIII inhibitor: fatal bleeding despite multimodal treatment including rituximab preceded by multiple plasmaphereses","volume":"101","author":"Fischer","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.biopha.2004.04.006_BIB48","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1126\/science.2511630","article-title":"Thymic requirement for clonal deletion during T cell development","volume":"24","author":"Fry","year":"1989","journal-title":"Science"},{"key":"10.1016\/j.biopha.2004.04.006_BIB49","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1097\/00004397-200040010-00008","article-title":"Postoperative sympathetic ophthalmia","volume":"40","author":"Gasch","year":"2000","journal-title":"Int Ophthalmol Clin"},{"key":"10.1016\/j.biopha.2004.04.006_BIB50","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1046\/j.1365-2141.2002.3406_2.x","article-title":"Complete, long-term remission of refractory idiopathic cold haemagglutinin disease after Mabthera","volume":"117","author":"Gharib","year":"2002","journal-title":"Br J Haematol"},{"key":"10.1016\/j.biopha.2004.04.006_BIB51","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1182\/blood.V99.3.1092","article-title":"Successful treatment of pure red cell aplasia with rituximab in patients with chronic lymphocytic leukemia","volume":"99","author":"Ghazal","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.biopha.2004.04.006_BIB52","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1034\/j.1600-0609.2002.02686.x","article-title":"Treatment of relapsed idiopathic thrombocytopenic purpura with the anti-CD20 monoclonal antibody rituximab: a pilot study","volume":"69","author":"Giagounidis","year":"2002","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.biopha.2004.04.006_BIB53","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.1182\/blood.V98.12.3383","article-title":"CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59","volume":"98","author":"Golay","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.biopha.2004.04.006_BIB54","first-page":"1002","article-title":"Rituximab-mediated antibody-dependent cellular cytotoxicity against neoplastic B cells is stimulated strongly by interleukin-2","volume":"88","author":"Golay","year":"2003","journal-title":"Haematologica"},{"key":"10.1016\/j.biopha.2004.04.006_BIB55","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/S0022-2143(99)90164-6","article-title":"Clinical applications of anti-CD20 antibodies","volume":"134","author":"Gopal","year":"1999","journal-title":"J Lab Clin Med"},{"key":"10.1016\/j.biopha.2004.04.006_BIB56","doi-asserted-by":"crossref","unstructured":"Gorge JN, Vesely SK. Thrombotic thrombocytopenic purpura: from the benh to the bedside, not yet to the community. Ann Intern Med 203;138:152\u20133.","DOI":"10.7326\/0003-4819-138-2-200301210-00018"},{"key":"10.1016\/j.biopha.2004.04.006_BIB57","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1080\/08880010390232781","article-title":"Successful induction and maintenance of long-term remission in a child with chronic relapsing autoimmune hemolytic anemia using rituximab","volume":"20","author":"Gottardo","year":"2003","journal-title":"Pediatr Hematol Oncol"},{"key":"10.1016\/j.biopha.2004.04.006_BIB58","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2174\/1389201003379059","article-title":"Rituximab: the first monoclonal antibody approved for the treatment of lymphoma","volume":"1","author":"Grillo-Lopez","year":"2000","journal-title":"Curr Pharm Biotechnol"},{"key":"10.1016\/j.biopha.2004.04.006_BIB59","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1006\/bcmd.2002.0522","article-title":"Rituximab therapy for refractory thrombotic thrombocytopenic purpura","volume":"28","author":"Gutterman","year":"2002","journal-title":"Blood Cells Mol Dis"},{"key":"10.1016\/j.biopha.2004.04.006_BIB60","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1080\/146532401753174098","article-title":"The CD52 antigen and development of the CAMPATH antibodies","volume":"3","author":"Hale","year":"2001","journal-title":"Cytotherapy"},{"key":"10.1016\/j.biopha.2004.04.006_BIB61","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1182\/blood.V100.6.2260","article-title":"Rituximab treatment of refractory fludarabine-associated immune thrombocytopenia in chronic lymphocytic leukemia","volume":"100","author":"Hegde","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.biopha.2004.04.006_BIB62","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1002\/ajh.10309","article-title":"Successful treatment of a patient with hairy cell leukemia and pentostatin-induced autoimmune thrombocytopenia with rituximab","volume":"73","author":"Hensel","year":"2003","journal-title":"Am J Hematol"},{"key":"10.1016\/j.biopha.2004.04.006_BIB63","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1046\/j.1365-2133.2003.05209_10.x","article-title":"Treatment of pemphigus vulgaris with anti-CD20 monoclonal antibody (rituximab)","volume":"148","author":"Herrmann","year":"2003","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.biopha.2004.04.006_BIB64","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1046\/j.1365-2141.2003.04478.x","article-title":"Rituximab effective in a patient with refractory autoimmune haemolytic anaemia and CD20-negative multiple myeloma","volume":"122","author":"Hofer","year":"2003","journal-title":"Br J Haematol"},{"key":"10.1016\/j.biopha.2004.04.006_BIB65","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1038\/sj.bmt.1703551","article-title":"Successful treatment of refractory autoimmune haemolytic anaemia in a post-unrelated bone marrow transplant paediatric patient with rituximab","volume":"29","author":"Hongeng","year":"2002","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.biopha.2004.04.006_BIB66","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1182\/blood.V99.3.1096a","article-title":"Sustained response of refractory chronic lymphocytic leukemia in progression complicated by acute hemolitic anemia to anti-CD20 monoclonal antibody","volume":"99","author":"Iannitto","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.biopha.2004.04.006_BIB67","first-page":"482","article-title":"Rituximab: a new therapeutic tool for primary immune thrombocytopenic purpura?","volume":"8","author":"Introna","year":"2003","journal-title":"Haematologica"},{"key":"10.1016\/j.biopha.2004.04.006_BIB68","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1080\/1042819021000055110","article-title":"Severe autoimmune hemolytic anemia following rituximab therapy in a patient with a lymphoproliferative disorder","volume":"44","author":"Jourdan","year":"2003","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.biopha.2004.04.006_BIB69","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1159\/000070973","article-title":"Life-threatening bleeding from refractory acquired FVIII inhibitor successfully treated with rituximab","volume":"109","author":"Jy","year":"2003","journal-title":"Acta Haematol"},{"key":"10.1016\/j.biopha.2004.04.006_BIB70","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1074\/jbc.270.22.13099","article-title":"Expression of calcium-permeable cation channel CD20 accelerates progression through the phase G1 phase in Balb\/c 3T3 cells","volume":"270","author":"Kanzaki","year":"1995","journal-title":"J Biol Chem"},{"key":"10.1016\/j.biopha.2004.04.006_BIB71","first-page":"31","article-title":"Idiopathic thrombocytopenic purpura associated with mantle cell lymphoma showing an increase in the platelet count receiving anti-CD20 antibody rituximab","volume":"44","author":"Kawachi","year":"2003","journal-title":"Rinsho Ketsueki"},{"key":"10.1016\/j.biopha.2004.04.006_BIB72","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1078\/0171-2985-00200","article-title":"Effective B cell depletion with rituximab in the treatment of autoimmune diseases","volume":"206","author":"Kneitz","year":"2002","journal-title":"Immunobiology"},{"key":"10.1016\/j.biopha.2004.04.006_BIB73","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1055\/s-2003-41131","article-title":"Antibody-associated polyneuropathy syndromes: principles and treatment","volume":"23","author":"Kornberg","year":"2003","journal-title":"Semin Neurol"},{"key":"10.1016\/j.biopha.2004.04.006_BIB74","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/S0952-7915(01)00272-2","article-title":"The T-cell repertoire available for recognition of self-antigens","volume":"13","author":"Kreuwel","year":"2001","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.biopha.2004.04.006_BIB75","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1038\/sj.leu.2401976","article-title":"Remission of severe cold agglutinin disease after rituximab therapy","volume":"15","author":"Layios","year":"2001","journal-title":"Leukemia"},{"key":"10.1016\/j.biopha.2004.04.006_BIB76","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1136\/ard.61.10.883","article-title":"Clinical outcome in 22\u00a0patients with rheumatoid arthritis treated with B lymphocyte depletion","volume":"61","author":"Leandro","year":"2002","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.biopha.2004.04.006_BIB77","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/sj.bmt.1703102","article-title":"Changes in autoimmune thyroid disease following allogeneic bone marrow transplantation","volume":"28","author":"Lee","year":"2001","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.biopha.2004.04.006_BIB78","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/nm0502-509","article-title":"Autoimmunity due to molecular mimicry as a cause of neurological disease","volume":"8","author":"Levin","year":"2002","journal-title":"Nat Med"},{"key":"10.1016\/j.biopha.2004.04.006_BIB79","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1212\/WNL.52.8.1701","article-title":"IgM antibody-related polyneuropathies: B-cell depletion chemotherapy using rituximab","volume":"52","author":"Levine","year":"1999","journal-title":"Neurology"},{"key":"10.1016\/j.biopha.2004.04.006_BIB80","first-page":"1962","article-title":"Fatal cytokine release syndrome with chimeric anti-CD20 monoclonal antibody rituximab in a 71-year-old patient with chronic lymphocytic leukemia","volume":"17","author":"Lim","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.biopha.2004.04.006_BIB81","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1093\/rheumatology\/keg424","article-title":"Remission induction in Behcet\u2019s disease following lymphocyte depletion by the anti-CD52 antibody CAMPATH 1-H","volume":"42","author":"Lockwood","year":"2003","journal-title":"Rheumatology (Oxford)"},{"issue":"1\u00a0Suppl 2","key":"10.1016\/j.biopha.2004.04.006_BIB82","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1053\/sonc.2002.30156","article-title":"Rituximab: mechanism of action and resistance","volume":"29","author":"Maloney","year":"2002","journal-title":"Semin Oncol"},{"key":"10.1016\/j.biopha.2004.04.006_BIB83","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/sj.bmt.1703833","article-title":"Refractory Evans\u2019 syndrome treated with allogeneic SCT followed by DLI. Demonstration of a graft-versus-autoimmunity effect","volume":"31","author":"Marmont","year":"2003","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.biopha.2004.04.006_BIB84","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/sj.thj.6200199","article-title":"Efficacy of rituximab in the treatment of refractory chronic lymphocytic leukemia patient with bone marrow aplasia","volume":"3","author":"Marotta","year":"2002","journal-title":"Hematol J"},{"key":"10.1016\/j.biopha.2004.04.006_BIB85","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/sj.bmt.1703668","article-title":"Successful treatment of pure red cell aplasia with a single dose of rituximab in a child after major ABO incompatible peripheral blood allogeneic stem cell transplantation for acquired aplastic anemia","volume":"30","author":"Maschan","year":"2002","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.biopha.2004.04.006_BIB86","first-page":"3862","article-title":"Exacerbation of lupus while receiving rituximab for chronic refractory thrombocytopenia","volume":"98","author":"Mehta","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.biopha.2004.04.006_BIB87","first-page":"421","article-title":"Rituximab treatment of chronic idiopathic thrombocytopenic purpura","volume":"93","author":"Meo","year":"2002","journal-title":"Recenti Prog Med"},{"key":"10.1016\/j.biopha.2004.04.006_BIB88","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1177\/030006059702500409","article-title":"Antithymocyte globulin for a patient with systemic lupus erythematosus complicated by severe pancytopenia","volume":"25","author":"Morishita","year":"1997","journal-title":"J Int Med Res"},{"key":"10.1016\/j.biopha.2004.04.006_BIB89","doi-asserted-by":"crossref","first-page":"3478","DOI":"10.1182\/blood-2002-01-0018","article-title":"Mixed warm and cold autoimmune hemolytic anemia: complete recovery after two courses of rituximab treatment","volume":"99","author":"Morselli","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.biopha.2004.04.006_BIB90","first-page":"1006","article-title":"Rituximab for refractory childhood autoimmune hemolytic anemia","volume":"4","author":"Motto","year":"2002","journal-title":"IMAJ"},{"key":"10.1016\/j.biopha.2004.04.006_BIB91","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1097\/00043426-200304000-00019","article-title":"Report of a child with vitiligo and Evans syndrome","volume":"25","author":"Muwakkit","year":"2003","journal-title":"J Pediatr Hematol Oncol"},{"key":"10.1016\/j.biopha.2004.04.006_BIB92","doi-asserted-by":"crossref","first-page":"2364","DOI":"10.1182\/blood-2002-12-3908","article-title":"High-dose immunosuppressive therapy and autologous peripheral blood stem cell transplantation for severe multiple sclerosis","volume":"102","author":"Nash","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.biopha.2004.04.006_BIB93","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1136\/adc.88.4.337","article-title":"Anti B cell targeted immunotherapy for treatment of refractory autoimmune haemolytic anaemia in a young infant","volume":"88","author":"Ng","year":"2003","journal-title":"Arch Dis Child"},{"key":"10.1016\/j.biopha.2004.04.006_BIB94","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1067\/mjd.2003.581","article-title":"Evaluating the role of immunoablative high-dose cyclophosphamide therapy in pemphigus vulgaris","volume":"49","author":"Nousari","year":"2003","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.biopha.2004.04.006_BIB95","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s002510050412","article-title":"Mice carrying a CD20 gene disruption","volume":"48","author":"O\u2019Keefe","year":"1998","journal-title":"Immunogenetics"},{"issue":"Suppl 1","key":"10.1016\/j.biopha.2004.04.006_BIB96","doi-asserted-by":"crossref","first-page":"S81","DOI":"10.1038\/sj.bmt.1703950","article-title":"Allogeneic stem cell transplantation for autoimmune diseases: nonmyeloablative conditioning regimens","volume":"32","author":"Oyama","year":"2003","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.biopha.2004.04.006_BIB97","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1182\/blood.V99.4.1314","article-title":"The chimeric anti-CD20 antibody rituximab induces apoptosis in B-cell chronic lymphocytic leukemia cells through a p38 mitogen activated protein-kinase-dependent mechanism","volume":"99","author":"Pedersen","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.biopha.2004.04.006_BIB98","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1046\/j.1365-2141.2002.03278.x","article-title":"Anti-CD20 monoclonal antibody (rituximab) for life-threatening autoimmune haemolytic anaemia in a patient with systemic lupus erythematosus","volume":"116","author":"Perrotta","year":"2002","journal-title":"Br J Haematol"},{"key":"10.1016\/j.biopha.2004.04.006_BIB99","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1136\/jnnp.74.4.485","article-title":"Treatment of IgM antibody associated polyneuropathies using rituximab","volume":"74","author":"Pestronk","year":"2003","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.biopha.2004.04.006_BIB100","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1055\/s-2001-17109","article-title":"\u201cCatastrophic systemic lupus erythematosus\u201d with Rosai-Dorfman sinus histiocytosis. Successful treatment with anti-CD20\/rutuximab","volume":"126","author":"Petschner","year":"2001","journal-title":"Dtsch Med Wochenschr"},{"key":"10.1016\/j.biopha.2004.04.006_BIB101","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S1083-8791(03)00216-7","article-title":"Treatment of chronic graft-versus-host disease with anti-CD20 chimeric monoclonal antibody","volume":"9","author":"Ratanatharathorn","year":"2003","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.biopha.2004.04.006_BIB102","doi-asserted-by":"crossref","first-page":"275","DOI":"10.7326\/0003-4819-133-4-200008150-00011","article-title":"Anti-CD20 chimeric monoclonal antibody treatment of refractory immune-mediated thrombocytopenia in a patient with chronic graft-versus-host disease","volume":"133","author":"Ratanatharathorn","year":"2000","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.biopha.2004.04.006_BIB103","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1046\/j.1440-1711.2003.01188.x","article-title":"Fcgamma receptors in the initiation and progression of systemic lupus erythematosus","volume":"81","author":"Reefman","year":"2003","journal-title":"Immunol Cell Biol"},{"key":"10.1016\/j.biopha.2004.04.006_BIB104","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1182\/blood.V83.2.435.435","article-title":"Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20","volume":"83","author":"Reff","year":"1994","journal-title":"Blood"},{"key":"10.1016\/j.biopha.2004.04.006_BIB105","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1002\/mus.10359","article-title":"Rituximab in the treatment of polyneuropathy associated with anti-MAG antibodies","volume":"27","author":"Renaud","year":"2003","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.biopha.2004.04.006_BIB106","first-page":"262","article-title":"Rituximab in the treatment of relapsing idiopathic thrombocytopenic purpura","volume":"61","author":"Riksen","year":"2003","journal-title":"Neth J Med"},{"key":"10.1016\/j.biopha.2004.04.006_BIB107","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0065-2776(02)80012-8","article-title":"Protein degradation and the generation of MHC class I-presented peptides","volume":"80","author":"Rock","year":"2002","journal-title":"Adv Immunol"},{"issue":"6\u00a0Suppl 12","key":"10.1016\/j.biopha.2004.04.006_BIB108","first-page":"99","article-title":"A pilot study of the anti-CD20 monoclonal antibody rituximab in patients with refractory immune thrombocytopenia","volume":"27","author":"Saleh","year":"2000","journal-title":"Semin Oncol"},{"key":"10.1016\/j.biopha.2004.04.006_BIB109","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1067\/mjd.2002.126273","article-title":"Anti-CD20 chimeric monoclonal antibody (rituximab) for the treatment of recalcitrant, life-threatening pemphigus vulgaris with implications in the pathogenesis of the disorder","volume":"47","author":"Salopek","year":"2002","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.biopha.2004.04.006_BIB110","doi-asserted-by":"crossref","first-page":"3818","DOI":"10.1182\/blood-2002-10-3162","article-title":"Monoclonal antibody treatment of mixed cryoglobulinemia resistant to interferon alpha with an anti-CD20","volume":"101","author":"Sansonno","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.biopha.2004.04.006_BIB111","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1007\/s004310100778","article-title":"Autologous peripheral blood stem cell transplantation and anti-B-cell directed immunotherapy for refractory auto-immune haemolytic anaemia","volume":"160","author":"Seeliger","year":"2001","journal-title":"Eur J Pediatr"},{"key":"10.1016\/j.biopha.2004.04.006_BIB112","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1007\/s002770000251","article-title":"Effective treatment with rituximab in a patient with refractory prolymphocytoid transformed B-chronic lymphocytic leukemia and Evans syndrome","volume":"80","author":"Seipelt","year":"2001","journal-title":"Ann Hematol"},{"key":"10.1016\/j.biopha.2004.04.006_BIB113","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1182\/blood.V91.5.1644","article-title":"Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies","volume":"91","author":"Shan","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.biopha.2004.04.006_BIB114","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1182\/blood.V96.3.1184.015k54_1184_1186","article-title":"Pure red cell aplasia due to parvovirus B19 in a patient treated with rituximab","volume":"96","author":"Sharma","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.biopha.2004.04.006_BIB115","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1038\/nri821","article-title":"CD4+ CD25+ suppressor T cells: more questions than answers","volume":"2","author":"Shevach","year":"2002","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.biopha.2004.04.006_BIB116","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1038\/ni803","article-title":"Role of BCR affinity in T cell dependent antibody responses in vivo","volume":"3","author":"Shih","year":"2002","journal-title":"Nat Immunol"},{"key":"10.1016\/j.biopha.2004.04.006_BIB117","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1097\/00003072-200202000-00019","article-title":"F-18 FDG positron emission tomography demonstrates resolution of non-Hodgkin\u2019s lymphoma of the parotid gland in a patient with Sjogren\u2019s syndrome: before and after anti-CD20 antibody rituximab therapy","volume":"27","author":"Shih","year":"2002","journal-title":"Clin Nucl Med"},{"key":"10.1016\/j.biopha.2004.04.006_BIB118","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1046\/j.1365-2141.2003.04446.x","article-title":"Rituximab reduces relapse risk after allogenic and autologous stem cell transplantation in patients with high-risk aggressive non-Hodgkin\u2019s lymphoma","volume":"122","author":"Shimoni","year":"2003","journal-title":"Br J Haematol"},{"key":"10.1016\/j.biopha.2004.04.006_BIB119","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/sj.bmt.1703371","article-title":"Anti-CD20 monoclonal antibody therapy for autoimmune hemolytic anemia following T cell-depleted, haplo-identical stem cell transplantation","volume":"29","author":"Ship","year":"2002","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.biopha.2004.04.006_BIB120","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1002\/ajh.1112","article-title":"Successful treatment with rituximab for relapsing immune thrombocytopenic purpura (ITP) associated with low-grade non-Hodgkin\u2019s lymphoma","volume":"67","author":"Shvidel","year":"2001","journal-title":"Am J Hematol"},{"issue":"6","key":"10.1016\/j.biopha.2004.04.006_BIB121","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1002\/art.10947","article-title":"Rituximab therapy and autoimmune disorders: prospects for anti-B cell therapy","volume":"48","author":"Silverman","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.biopha.2004.04.006_BIB122","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1002\/art.11109","article-title":"Improvement in Sjogren\u2019s syndrome following therapy with rituximab for marginal zone lymphoma","volume":"49","author":"Somer","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.biopha.2004.04.006_BIB123","first-page":"1405","article-title":"Remission of cold hemagglutinin disease induced by rituximab therapy","volume":"164","author":"Sparling","year":"2001","journal-title":"CMAJ"},{"key":"10.1016\/j.biopha.2004.04.006_BIB124","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1182\/blood.V98.4.952","article-title":"Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura","volume":"98","author":"Stasi","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.biopha.2004.04.006_BIB125","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/sj.bmt.1703654","article-title":"Combination treatment of bullous pemphigoid with anti-CD20 and anti-CD25 antibodies in a patient with chronic graft-versus-host disease","volume":"30","author":"Szabolcs","year":"2002","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.biopha.2004.04.006_BIB126","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S1471-4892(03)00032-8","article-title":"Antibody therapy for rheumatoid arthritis","volume":"3","author":"Taylor","year":"2003","journal-title":"Curr Opin Pharmacol"},{"key":"10.1016\/j.biopha.2004.04.006_BIB127","first-page":"223","article-title":"Rituximab chimeric anti-CD20 monoclonal antibody treatment for refractory hemolytic anemia in patients with lymphoproliferative disorders","volume":"88","author":"Trape","year":"2003","journal-title":"Haematologica"},{"key":"10.1016\/j.biopha.2004.04.006_BIB128","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1034\/j.1600-0609.2003.00026.x","article-title":"Rituximab induces remission of cerebral ischemia caused by thrombotic thrombocytopenic purpura","volume":"70","author":"Tsai","year":"2003","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.biopha.2004.04.006_BIB129","first-page":"ELT24","article-title":"Anti-CD20 monoclonal antibody (rituximab) in the treatment of autoimmune diseases. Successful result in refractory pemphigus vulgaris: report of a case","volume":"88","author":"Virgolini","year":"2003","journal-title":"Haematologica"},{"key":"10.1016\/j.biopha.2004.04.006_BIB130","first-page":"4668a","article-title":"Acute agranulocytosis (AA) in three patients treated with rituximab for non-Hodgkin lymphoma","volume":"98","author":"Voog","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.biopha.2004.04.006_BIB131","first-page":"377","article-title":"Drug-induced hemolytic anemia","volume":"8","author":"Wautier","year":"2001","journal-title":"Transfus Clin Biol"},{"key":"10.1016\/j.biopha.2004.04.006_BIB132","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1191\/0961203303lu449cr","article-title":"Successful long-term treatment of systemic lupus erythematosus with rituximab maintenance therapy","volume":"12","author":"Weide","year":"2003","journal-title":"Lupus"},{"issue":"9","key":"10.1016\/j.biopha.2004.04.006_BIB133","doi-asserted-by":"crossref","first-page":"3426","DOI":"10.1182\/blood-2002-03-0765","article-title":"Rituximab in the treatment of acquired factor VIII inhibitors","volume":"100","author":"Wiestner","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.biopha.2004.04.006_BIB134","doi-asserted-by":"crossref","first-page":"2759","DOI":"10.4049\/jimmunol.168.6.2759","article-title":"CD40 ligand functions non-cell autonomously to promote deletion of self-reactive thymocytes","volume":"168","author":"Williams","year":"2002","journal-title":"J Immunol"},{"key":"10.1016\/j.biopha.2004.04.006_BIB135","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1080\/1042819031000067936","article-title":"Treatment of relapsing refractory diffuse large cell lymphoma after matched unrelated donor bone marrow transplant with immunosuppression withdrawal and rituximab","volume":"44","author":"Wong","year":"2003","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.biopha.2004.04.006_BIB136","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1046\/j.1529-8019.2003.01631.x","article-title":"Blistering disorders: diagnosis and treatment","volume":"16","author":"Yeh","year":"2003","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.biopha.2004.04.006_BIB137","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1191\/0961203302lu148ed","article-title":"B cells underpin lupus immunopathology","volume":"11","author":"Youinou","year":"2002","journal-title":"Lupus"},{"key":"10.1016\/j.biopha.2004.04.006_BIB138","doi-asserted-by":"crossref","first-page":"3827","DOI":"10.1182\/blood-2002-09-2856","article-title":"Efficacy and safety of rituximab in type II mixed cryoglobulinemia","volume":"101","author":"Zaja","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.biopha.2004.04.006_BIB139","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1002\/art.10345","article-title":"Rituximab for the treatment of type II mixed cryoglobulinemia","volume":"46","author":"Zaja","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.biopha.2004.04.006_BIB140","first-page":"189","article-title":"B-cell depletion with rituximab as treatment for immune hemolytic anemia and chronic thrombocytopenia","volume":"87","author":"Zaja","year":"2002","journal-title":"Haematologica"},{"key":"10.1016\/j.biopha.2004.04.006_BIB141","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1046\/j.1365-2141.2001.0115_1cr-4.x","article-title":"Rituximab in a case of cold agglutinin disease","volume":"115","author":"Zaja","year":"2001","journal-title":"Br J Haematol"},{"key":"10.1016\/j.biopha.2004.04.006_BIB142","first-page":"1157","article-title":"Rituximab for the treatment of type II mixed cryoglobulinemia","volume":"84","author":"Zaja","year":"1999","journal-title":"Haematologica"},{"key":"10.1016\/j.biopha.2004.04.006_BIB143","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1212\/WNL.55.7.1062-a","article-title":"Rituximab for myasthenia gravis developing after bone marrow transplant","volume":"55","author":"Zaja","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/j.biopha.2004.04.006_BIB144","first-page":"538","article-title":"B-cell compartment as the selective target for the treatment of immune thrombocytopenias","volume":"88","author":"Zaja","year":"2003","journal-title":"Haematologica"},{"key":"10.1016\/j.biopha.2004.04.006_BIB145","doi-asserted-by":"crossref","first-page":"3995","DOI":"10.1182\/blood.V97.12.3995","article-title":"Anti-CD20 monoclonal antibody for the treatment of severe, immune-mediated, pure red cell aplasia and hemolytic anemia","volume":"97","author":"Zecca","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.biopha.2004.04.006_BIB146","doi-asserted-by":"crossref","first-page":"105","DOI":"10.7326\/0003-4819-138-2-200301210-00011","article-title":"Remission of chronic thrombotic thrombocytopenic purpura after treatment with cyclophosphamide and rituximab","volume":"138","author":"Zheng","year":"2003","journal-title":"Ann Intern Med"}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332204000617?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332204000617?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T10:31:48Z","timestamp":1760092308000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332204000617"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,6]]},"references-count":146,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2004,6]]}},"alternative-id":["S0753332204000617"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2004.04.006","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2004,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rituximab in autoimmune diseases","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2004.04.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"converted-article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2004 \u00c9ditions scientifiques et m\u00e9dicales Elsevier SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}